Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00. Following the completion of the transaction, the insider directly owned 137,643 shares of the company’s stock, valued at approximately $30,065,360.49. This represents a 2.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The shares were sold at an average price of $204.10, for a total value of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $202.30, for a total value of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $186,778.95.

Natera Price Performance

NASDAQ:NTRA opened at $222.10 on Friday. The company has a market capitalization of $31.81 billion, a price-to-earnings ratio of -136.26 and a beta of 1.56. The business has a 50 day moving average of $203.83 and a 200 day moving average of $216.07. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp increased its holdings in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the period. Franklin Resources Inc. raised its position in Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Finally, Coatue Management LLC raised its position in Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. BTIG Research decreased their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. JPMorgan Chase & Co. upped their price target on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Morgan Stanley reduced their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.12.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.